admin – Page 3366 – Get News Story

New York Businesses Boost Financial Stability with IBN Technologies’ Expert Accounting and Bookkeeping Services Amid Economic Shifts

“Accounting and Bookkeeping Services (USA)”

New York businesses use Accounting and Bookkeeping Services to overcome rising costs, regulatory changes, and financial complexity. Expert solutions support compliance, improve cash flow, reduce overhead, and enhance financial accuracy, helping companies navigate challenges and focus on growth while maintaining stability and operational efficiency.

The need for bookkeeping and accounting services remains on the increase among New York State companies due to ongoing issues like inflation, labor shortages, and strict regulatory requirements. With today’s unstable economy, clear financial management is crucial for companies to manage cash flow, minimize risks, and stay compliant. With internal operational expenses increasing, more companies are opting to outsource their accounting needs to specialist providers with consistent accounting and bookkeeping services. Proper financial management is increasingly becoming the cornerstone of business stability, strategic management, and long-term success.

IBN Technologies gives New York companies the power to ride over financial hurdles through the provision of expert bookkeeping and accounting solutions. Relying on extensive sectoral know-how and a keen sense of financial compliance, IBN Technologies guides companies through the complexities of compliance regulations, processes automation, and accurate record-keeping. Their budget-friendly bookkeeping services offer scalable solutions that enable companies to concentrate on intrinsic growth programs while leaving finances to experts. Through state-of-the-art technology and a highly skilled offshore accounting staff, they keep clients in compliance, enhance cash flow management strategic decisions to grow. Using state-of-the-art technology and a skilled offshore accounting staff, they ensure clients stay in compliance, improve cash flow management, and support strategic decisions for growth.

Get 20 Free Hours and Transform Your Bookkeeping Efficiency

Start Your Free Trial: https://www.ibntech.com/free-trial/

Employing Expert Accounting Services to Overcome Financial Challenges

As New York businesses are confronted with extraordinary financial challenges, professional bookkeeping and accounting services become more and more crucial. Volatile regulations, uncertain market environments, and increasing operating costs make it ever more challenging to accurately and timely maintain financial records in-house. Companies are looking for answers to some of these key issues:

•The challenge of keeping accurate financial records in a changing regulatory framework.

• Constant changes in tax laws lead to confusion and potential compliance risks.

• Ongoing cash flow management challenges affecting operational viability.

• Excessive expense of creating and maintaining internal accounting staff.

• Sophisticated financial responsibilities within highly regulated sectors.

To solve these pressing pain points, most organizations in New York are looking for firms that provide seasoned accounting and bookkeeping services. IBN Technologies is unique in providing customized financial solutions with a focus to cater to industry-specific needs. By providing end-to-end services, businesses can concentrate on pursuing growth targets, while experienced professionals take care of intricate financial management operations.

“Strong financial management is not an option — it is essential for success. Professional accounting services equip businesses with the insights and security they need to navigate an unpredictable financial landscape,” stated Ajay Mehta, CEO of IBN Technologies.

Accounting and Bookkeeping Services from IBN Technologies

IBN Technologies offers the complete spectrum of accounting and bookkeeping services optimized for small and mid-sized enterprises throughout New York State and globally. Their offerings allow businesses to streamline processes, stay compliant, and gain enhanced financial precision. With more than 25 years of experience, IBN Technologies presents scalable and trusted offshore bookkeeping services that answer the increasing requirements of contemporary organizations.

By using advanced software integration, expert teams, and a secure infrastructure, they service multiple systems such as QuickBooks, Sage, and Xero. CPA practices and businesses alike can benefit from solutions that minimize staff issues, optimize costs, and ensure consistent compliance.

IBN Technologies provides the following major services:

✅ Full-Service Accounting and Bookkeeping: Complete support from day-to-day transaction processing to detailed year-end reconciliations.

✅ Financial Reporting and Analysis: Detailed reports and analysis to facilitate improved decision-making and uncover business growth opportunities.

✅ Tax Filing Services: Preparation and submission of tax returns to guarantee complete compliance and reduce tax liabilities.

✅ Accounts Payable and Receivable Management: Bill and collection process streamlining to enhance cash flow and minimize penalties.

✅ Financial Consultation and Advisory: Strategic financial consultation to assist companies in cutting costs and increasing long-term profitability.

✅ Cloud-Based Accounting Solutions: Access to real-time financial information to enhance collaboration and facilitate virtual business operations.

Businesses across New York are increasingly looking for expert online bookkeeping services and offshore bookkeeping services to enhance financial management and operational efficiency. IBN Technologies’ rich experience, reliability, and affordable solutions make them the first choice for companies willing to outsource financial management to trusted professionals.

Optimizing Business Efficiency Through Professional Financial Management

Accurate accounting records help businesses make wise decisions, lower risk, and support strategic initiatives. By outsourcing accounting duties to IBN Technologies, businesses throughout New York can sharply decrease overhead, enhance operational effectiveness, and shift attention to growth.

✅ Provides comprehensive financial reporting for trend identification and strategic planning.

✅ Ensures regulatory compliance to avoid costly penalties.

✅ Reduces overhead by eliminating the need for in-house accounting teams.

Outsourcing accounting and bookkeeping services allow businesses to navigate financial complexities more effectively while focusing resources on innovation and growth.

Results That Build Trust: IBN Technologies Impact in Action

IBN Technologies has collaborated with businesses of every industry to deliver quantifiable outcomes. Its success stories reflect major cost reductions and operational efficiencies in numerous industries.

An Ohio construction company saved 60% of its monthly bookkeeping expenses and enhanced the accuracy of compliance reporting after it adopted IBN Technologies offshore bookkeeping services.

A company in Arizona has used IBN Technologies virtual bookkeeping services to process daily transactions automatically, which helped it close monthly books 80% quicker and free itself of reconciliation backlogs.

These results show not just cost savings, but measurable gains in operational efficiency and financial accuracy, both necessary for business growth.

Special Limited Time benefits for New Clients

To help more businesses experience the benefits of expert outsourcing, IBN Technologies is offering:

20 Free Hours of Bookkeeping Services – Available for a Limited Time Only!

During this free trial, their team will assess the business’s current financial processes, identify improvement areas, and deliver a customized implementation strategy without any upfront costs.

Get Expert Bookkeeping at Affordable Rates!

View Bookkeeping Plans: https://www.ibntech.com/pricing/

As the financial landscape continues to evolve, businesses will increasingly rely on expert bookkeeping and accounting services to navigate these changes. By leveraging professional financial management, companies can lower operational costs, optimize cash flow, ensure compliance, and stay ahead of regulatory shifts. Partnering with trusted IBN Technologies allows businesses to focus on growth, streamline processes, and make informed, data-driven decisions for sustained success.

As the demand for specialized financial expertise grows, companies must seek affordable, scalable solutions customized to their needs. Organizations can reduce risks, get helpful insights, and keep accurate financial records by working with experienced service providers like IBN Technologies.

This proactive approach will help businesses thrive in the face of industry challenges and market fluctuations, positioning them for long-term success and growth.

Related Services:      

Outsourced Finance and Accounting: https://www.ibntech.com/finance-and-accounting-services/      

About IBN Technologies           

IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive efficiency and growth.           

Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: 844-644-8440
Address:66, West Flagler Street Suite 900 Miami, FL, USA 33130
City: Miami
State: Florida
Country: United States
Website: https://www.ibntech.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New York Businesses Boost Financial Stability with IBN Technologies’ Expert Accounting and Bookkeeping Services Amid Economic Shifts

Non-Hodgkin’s Lymphoma Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in the Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin’s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin’s Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Non-Hodgkin’s Lymphoma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Non-Hodgkin’s Lymphoma Pipeline Outlook

Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report

In April 2025, Hoffmann-La Roche announced a phase Ib study in order to assess the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) for this combination treatment and to evaluate the general safety, tolerability, pharmacokinetic (PK), pharmacodynamic, and preliminary anti-tumor activity of this combination treatment in adult patients.
In March 2025, Hoffmann-La Roche conducted a phase I/II Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-cell Non-hodgkin’s Lymphoma.
In March 2025, Bristol-Myers Squibb organized a phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
DelveInsight’s Non-Hodgkin Lymphoma pipeline report depicts a robust space with 200+ Non-Hodgkin Lymphoma companies working to develop 220+ pipeline therapies for Non-Hodgkin Lymphoma treatment.
The leading Non-Hodgkin Lymphoma Companies such as Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.

Stay ahead with the most recent pipeline outlook for Non-Hodgkin’s Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin’s Lymphoma Treatment Drugs

Non-Hodgkin Lymphoma Emerging Drugs Profile

Mosunetuzumab: Hoffmann-la Roche

Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies. This results in crosslinking of the TCR, inducing downstream signaling events that lead to B-cell killing. Mosunetuzumab is equipped with structural features that promote T-cell recruitment and retention, resulting in an antitumor effect. In preclinical models, mosunetuzumab induced T-cell proliferation and B-cell death; furthermore, efficient B-cell killing was achieved at low effector-to-target (T cell:B cell) ratios. Use of mosunetuzumab in combination with PD-L1 inhibition may address adaptive immune resistance mechanisms to enhance anticancer activity against B-cell malignancies. The drug is being evaluated in Phase III Study to evaluate the efficacy and safety of Mosunetuzumab in combination with Polatuzumab Vedotin in comparison with rituximab in combination with gemcitabine plus oxaliplatin in participants with relapsed or refractory aggressive b-cell Non-Hodgkin’s Lymphoma.

Tisagenlecleucel: Novartis

Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient’s T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR is comprised of a murine single-chain antibody fragment (scFv) specific for CD19, followed by a CD8 hinge and transmembrane region that is fused to the intracellular signaling domains from 4-1BB (CD137) and CD3 zeta Label. These intracellular costimulatory signaling domains increase the expansion, longer-term persistence and potency of CAR T cells: the CD3 zeta component is critical for initiating T-cell activation and antitumor activity, while 4-1BB enhances the expansion and persistence of tisagenlecleucel {FDA Label, A20379]. Upon binding to CD19-expressing cells, the CAR transmits a signal to promote T-cell expansion, activation, target cell elimination, and persistence of the tisagenlecleucel cells. Currently, it is in Phase III stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.

Capivasertib: AstraZeneca

Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.

BI-1206: BioInvent

BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In January 2023, positive data was presented from the ongoing clinical Phase I/IIa study of BI-1206 in combination with rituximab for the treatment of non-Hodgkin’s lymphoma (NHL). Data suggest that BI-1206 restores activity of rituximab in relapsed NHL patients.

HMPL-760: Hutchmed

HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.

The Non-Hodgkin’s Lymphoma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin’s Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin’s Lymphoma Treatment.
Non-Hodgkin’s Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Non-Hodgkin’s Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin’s Lymphoma market

Explore groundbreaking therapies and clinical trials in the Non-Hodgkin’s Lymphoma Pipeline. Access DelveInsight’s detailed report now! @ New Non-Hodgkin’s Lymphoma Drugs

Non-Hodgkin’s Lymphoma Companies

Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences Inc. and others.

Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Parenteral
intravenous
Subcutaneous
Topical

Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of Non-Hodgkin’s Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Non-Hodgkin’s Lymphoma Market Drivers and Barriers

Scope of the Non-Hodgkin Lymphoma Pipeline Report

Coverage- Global
Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Non-Hodgkin Lymphoma Companies- Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc., Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd. Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.
Non-Hodgkin Lymphoma Pipeline Therapies- Bortezomib + Rituximab, Epcoritamab, Lenalidomide, Ibrutinib, GNC-038, ABT-199, Bendamustine, and others.

Get the latest on Non-Hodgkin’s Lymphoma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Non-Hodgkin’s Lymphoma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Non-Hodgkin’s Lymphoma Executive Summary
Non-Hodgkin Lymphoma: Overview
Non-Hodgkin’s Lymphoma Pipeline Therapeutics
Non-Hodgkin’s Lymphoma Therapeutic Assessment
Non-Hodgkin Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tisagenlecleucel: Novartis
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Capivasertib: AstraZeneca
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
BI-1206: BioInvent
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
HMPL-760: Hutchmed
Drug profiles in the detailed report…..
Preclinical Stage Products
Product Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Non-Hodgkin Lymphoma Key Companies
Non-Hodgkin Lymphoma Key Products
Non-Hodgkin Lymphoma- Unmet Needs
Non-Hodgkin Lymphoma- Market Drivers and Barriers
Non-Hodgkin Lymphoma- Future Perspectives and Conclusion
Non-Hodgkin Lymphoma Analyst Views
Non-Hodgkin Lymphoma Key Companies
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Hodgkin’s Lymphoma Pipeline Appears Robust With 200+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Liver Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Liver Cancer Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Liver Cancer pipeline landscape. It covers the Liver Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Liver Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Liver Cancer Pipeline Report to explore emerging therapies, key Liver Cancer Companies, and future Liver Cancer treatment landscapes @ Liver Cancer Pipeline Outlook Report

Key Takeaways from the Liver Cancer Pipeline Report

In May 2025, Hoffmann-La Roche announced a Phase Ib/II study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer.
In April 2025, Eureka Therapeutics Inc. announced a phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.
In April 2025, Eisai Inc. announced a study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).
DelveInsight’s Liver Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Liver Cancer treatment.
The leading Liver Cancer Companies such as Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb and others.
Promising Liver Cancer Therapies such as Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.

Discover how the Liver Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Liver Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Liver Cancer Clinical Trials and Studies

Liver Cancer Emerging Drugs Profile

Namodenoson: Can-Fite BioPharma

Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5′- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). Namodenoson’s mechanism of action is mediated via deregulation of the NF-κB and Wnt signal transduction pathways, resulting in the apoptosis of tumor cells. The protective effect of Namodenoson is mediated via down-regulation of the NF-kB signal transduction pathway and preventing apoptosis. Namodenoson has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation. The safety of Namodenoson has been demonstrated in preclinical studies, and Phase I and Phase II clinical studies demonstrating a favorable safety profile. Currently, the drug is in Phase III stage of its development for the treatment of advanced liver Cancer.

YIV-906: Yiviva

YIV-906 (also PHY906 or KD018) is a therapeutic candidate comprised of a proprietary cGMP botanical extract of four herbs inspired by a traditional Chinese medicine formulation used for over a millennium. YIV-906 has the potential to be developed as a platform oncology therapeutic when administered in combination with chemotherapy, immunotherapy and radiation therapies, in multiple cancer indications. YIV-906 has been shown to enhance immune function in the tumor microenvironment (by polarizing M1 macrophages and activating T cells), protect the gastrointestinal tract (by inhibiting inflammation via IL-6, NF-kappa-B, COX2, and iNOS pathways) and promote intestinal tissue repair (by increasing activity and expression of components of the Wnt signaling pathway). YIV-906 has been observed to enhance the anti-tumor activity of sorafenib in preclinical models of hepatocellular carcinoma and has shown promise in preliminary clinical studies in liver, pancreatic, colorectal and rectal cancers. Currently, the drug is in phase II stage of its clincal trial for the treatment of liver cancer.

TTI-101: Tvardi Therapeutics

TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in attenuating pY705-STAT3 phosphorylation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. Currently, the drug is in phase II stage of clinical trial.

STP707: Sirnaomics

STP707, our second key product, is in early-stage development for the treatment of solid tumors, liver cancer. STP707 is an intravenously administered TGF-ß1 and COX-2 inhibitor that leverages an RNAi-based response using the company’s proprietary PNP delivery platform. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer.

BST02: BioSyngen

BST02, a T cell therapy based on the expansion of the patient’s own tumor infiltrating lymphocytes, falls within the category of adoptive immune cell therapy technology. It holds promise for the treatment of all types of liver cancer, offering new hope for patients. In contrast to traditional TIL therapies, BST02 offers numerous benefits, including the ability to overcome distance constraints due to its cryopreserved form and the reduced need for high doses of interleukin-2. Currently, the drug is in Phase I stage of its clinical trial for the treatment of liver cancer.

The Liver Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Liver Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Liver Cancer Treatment.
Liver Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Liver Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Liver Cancer market.

Get a detailed analysis of the latest innovations in the Liver Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Liver Cancer Unmet Needs

Liver Cancer Companies

Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, Bristol-Myers Squibb and others.

Liver Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Liver Cancer Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Liver Cancer Therapies and key Liver Cancer Developments @ Liver Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Liver Cancer Pipeline Report

Coverage- Global
Liver Cancer Companies- Arcus Biosciences, Yiviva, Virogin Biotech, Tvardi Therapeutics, GlaxoSmithKline, TORL Biotherapeutics, AVEO Pharmaceuticals, Teclison, Epizyme, Sirnaomics, Coherus Biosciences, Sinocelltech Ltd., Qurient Co, Hoffmann-La Roche, Can-Fite BioPharma, Omega Therapeutics, Novita Pharmaceuticals, and Bristol-Myers Squibb, and others.
Liver Cancer Therapies- Atezolizumab, Bevacizumab, Tiragolumab, OH2 injection, MTL-CEBPA, Sorafenib 200mg, Lipiodol, Pemetrexed, Exatecan Mesylate, Brivanib, and others.
Liver Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Liver Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Liver Cancer drug development? Find out in DelveInsight’s exclusive Liver Cancer Pipeline Report—access it now! @ Liver Cancer Emerging Drugs and Major Companies

Table of Contents

Introduction
Executive Summary
Liver Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Liver Cancer – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Namodenoson: Can-Fite BioPharma
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
YIV-906: Yiviva
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
STP707: Sirnaomics
Mid Stage Products (Phase II)
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Liver Cancer – Collaborations Assessment- Licensing / Partnering / Funding
Liver Cancer – Unmet Needs
Liver Cancer – Market Drivers and Barriers
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Liver Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Head and Neck Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Head and Neck cancer Pipeline Insight 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Head and Neck cancer pipeline landscape. It covers the Head and Neck Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Head and Neck Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Head and Neck cancer Treatment Landscape. Click here to read more @ Head and Neck cancer Pipeline Outlook

Key Takeaways from the Head and Neck Cancer Pipeline Report

In May 2025, M.D. Anderson Cancer Center announced a clinical research study is to learn if RAD001 in combination with Tarceva (erlotinib hydrochloride) can help to control head and neck squamous cell cancer (HNSCC). The safety of this drug combination will also be studied.
In May 2025, Ascendis Pharma A/S conducted a study is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage III/IVA resectable locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). After surgery, participants will receive local standard-of-care treatment and will be followed for safety, efficacy, and survival for up to 2 years.
DelveInsight’s Head and Neck Cancer pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Head and Neck Cancer treatment.
The leading Head and Neck Cancer Companies such as Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
Promising Head and Neck Cancer Therapies such as RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.

Discover groundbreaking developments in Head and Neck Cancer Therapies! Gain in-depth knowledge of key Head and Neck Cancer Clinical trials, emerging drugs, and market opportunities @ Head and Neck Cancer Clinical Trials Assessment

Head and Neck Cancer Emerging Drugs Profile

Xevinapant: Debiopharm/Merck

Xevinapant is a potent, orally available, inhibitor of IAPs (Inhibitor of Apoptosis Proteins). IAP inhibitors restore sensitivity to apoptosis in cancer cells and thereby deprive them of one of their major resistance mechanisms. This class of products is therefore particularly suited to be combined with widely used but often sub-optimal chemo- and radiotherapy (CRT). As leader of the class, xevinapant established proof of efficacy in high-risk locally advanced squamous cell carcinoma of the head and neck (LASCCHN) patients for which the combination provided highly significant and sustainable clinical benefit as compared to CRT alone. Increasing tumor cell sensitivity to chemoradiotherapy constitutes a highly promising strategy for xevinapant which ultimately may improve treatment outcomes for these high-risk patients and other cancer patients currently treated with similar regimens. In addition to combination with CRT, xevinapant is also being investigated in combination with chemotherapy as well as checkpoint inhibitors. An exclusive license agreement has been granted to Merck in 2021 for its further development and commercialization. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Head and Neck cancer.

Dostarlimab: GlaxoSmithKline

Dostarlimab, developed by GlaxoSmithKline (GSK), is a humanized monoclonal antibody that targets the programmed death-1 (PD-1) receptor, enhancing the body’s immune response against various cancers, including head and neck cancer. It has shown promise in several clinical trials, particularly for cancers characterized by mismatch repair deficiency (dMMR) and microsatellite instability-high (MSI-H) statuses. Dostarlimab functions by inhibiting the interaction between PD-1 receptors on T-cells and their ligands (PD-L1) on tumor cells. This blockade allows T-cells to more effectively recognize and attack cancer cells, thereby promoting tumor regression. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Head and Neck cancer.

Tigilanol tiglate: QBiotics Group Limited

It is a short-chain diterpene ester isolated from the seed of Fontainea picrosperma, with potential antineoplastic activity. Upon intratumoral administration, tigilanol tiglate disrupts mitochondrial functioning and induces mitochondrial swelling, which leads to oncolysis of tumor cells that are in direct contact of the agent. In addition, tigilanol tiglate activates protein kinase C (PKC) signaling cascade, which leads to an acute inflammatory response. This results in hypoxia and activates innate immune cells including neutrophils and macrophages, thereby further killing tumor cells. The activation of the beta-II isoform of PKC (PKC beta II) also increases tumor vasculature permeability, which leads to the destruction of tumor vasculature. Currently, the drug is in the Phase II stage of development to treat Head and Neck cancer.

MEM-288: Memgen, Inc.

MEM-288 is an innovative oncolytic adenovirus developed by Memgen, Inc., designed as a cancer immunotherapy targeting solid tumors. It incorporates two key transgenes: human interferon beta (IFNβ) and a proprietary recombinant chimeric CD40 ligand (CD40L). This combination aims to enhance the immune system’s response against cancer cells, particularly in patients whose tumors have not responded to existing therapies, such as checkpoint inhibitors. Currently, the drug is in the Phase I stage of development to treat Head and Neck cancer.

The Head and Neck Cancer Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Head and Neck Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer Treatment.
Head and Neck Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Head and Neck Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Head and Neck Cancer Market

Stay informed about the Head and Neck Cancer Pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Head and Neck Cancer Unmet Needs

Head and Neck Cancer Companies

Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.

Head and Neck cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Head and Neck Cancer Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Transform your understanding of the Head and Neck Cancer Pipeline! See the latest progress in drug development and clinical research @ Head and Neck Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Head and Neck Cancer Pipeline Report

Coverage- Global
Head and Neck Cancer Companies- Debiopharm, Merck, GlaxoSmithKline, QBiotics Group Limited, Memgen, Inc., BioNTech, Alentis Therapeutics AG, Beijing CorreGene Biotechnology, Coordination Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Sichuan Baili Pharmaceutical Co., Ltd., TILT Biotherapeutics Ltd., Coherus Biosciences, Inc., and others.
Head and Neck Cancer Therapies- RiMO-301, Pembrolizumab, Dostarlimab, Belrestotug, Nelistotug, Methotrexate, Afatinib, and others.
Head and Neck Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Head and Neck Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Head and Neck Cancer Pipeline Analysis Today! @ Head and Neck Cancer Drugs and Companies

Table of Contents

Introduction
Executive Summary
Head and Neck Cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Xevinapant: Debiopharm/Merck
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Tigilanol tiglate: QBiotics Group Limited
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MEM-288: Memgen, Inc.
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company name
Drug profiles in the detailed report…..
Inactive Products
Head and Neck Cancer Key Companies
Head and Neck Cancer Key Products
Head and Neck Cancer – Unmet Needs
Head and Neck Cancer – Market Drivers and Barriers
Head and Neck Cancer – Future Perspectives and Conclusion
Head and Neck Cancer Analyst Views
Head and Neck Cancer Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Head and Neck Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Glioma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Glioma Pipeline. Dive into DelveInsight’s comprehensive report today! @ Glioma Pipeline Outlook

Key Takeaways from the Glioma Pipeline Report

In April 2025, Nerviano Medical Sciences announced a Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
In April 2025, Day One Biopharmaceuticals Inc. announced a phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in participants with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring first-line systemic therapy.
In April 2025, Eli Lilly and Company announced study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy. Your participation could last approximately 11 months and possibly longer depending upon how you and your tumor respond.
DelveInsight’s Glioma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioma treatment.
The leading Glioma Companies such as CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.
Promising Glioma Pipeline Therapies such as DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.

Stay ahead with the most recent pipeline outlook for Glioma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Glioma Treatment Drugs

Glioma Emerging Drugs Profile

AV-GBM-1: Aivita Biomedical, Inc.

AV-GBM-1 is an innovative immunotherapy developed by AIVITA Biomedical, Inc., specifically targeting glioblastoma (GBM), one of the most aggressive forms of brain cancer. This treatment utilizes autologous dendritic cells that are loaded with autologous tumor neoantigens derived from tumor-initiating cells. The therapy is administered through a series of subcutaneous injections and aims to enhance the immune response against the patient’s unique cancer profile. Currently, the drug is in phase III stage of its clinical trial for the treatment of Glioma.

DB 107: Denovo BioPharma

Denovo BioPharma’s DB107 is an investigational gene therapy designed to treat high-grade gliomas, including glioblastoma (GBM), a particularly aggressive form of brain cancer. The therapy utilizes a novel biomarker-guided approach, leveraging the Denovo Genomic Marker 7 (DGM7) to identify patients who are likely to benefit from the treatment. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.

MDNA55: Medicenna Therapeutics, Inc.

MDNA55 is a therapeutic for recurrent glioblastoma multiforme (rGBM), a uniformly fatal form of brain cancer. By using a highly specific IL-4 Superkine as the vehicle to deliver a potent bacterial toxin to the tumor cells, MDNA55 has the potential to purge bulk tumors and disrupt their supporting networks, while reactivating the immune system to tackle cancer. MDNA55 is designed to be a molecular trojan horse. It is a genetic fusion of two molecules: a circularly permuted IL-4 Superkine and the catalytic domain of the pseudomonas exotoxin A. Genetic fusion allows MDNA55 to harness the selectivity of the Superkine for cancers that overexpress the target IL-4 receptor (IL-4R) and deliver the cell-killing toxin directly into the tumor, its microenvironment and cancer stem cells. Since the IL-4 receptor is not found in a healthy brain and the exotoxin is only active in the cancer cell cytoplasm, this helps ensure that healthy cells are unaffected. When MDNA55 binds the target IL-4R, it is swallowed inside the tumor cell through a process called endocytosis. Once inside the tumor, proteases cleave the drug and activate the catalytic domain of the exotoxin to begin the process of apoptosis (cell death) involving a protein called elongation factor-2. Currently, the drug is in phase II stage of its clinical trial for the treatment of Glioma.

Abemaciclib: Eli Lilly and Company

Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with Fulvestrant. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.

NMS-03305293: Nerviano Medical Sciences

NMS-293 is a second generation PARP inhibitor that differentiates from other approved or advanced molecules in its unique selectivity for PARP1 vs. PARP2 enzymes and low DNA trapping activity, both features potentially linked to lower hematological toxicity and higher potential for combination with DNA damaging agents in a wide range of tumors, covering high unmet medical needs. It also has a superior ability to penetrate the blood-brain barrier, a very important feature supporting its utilization in CNS tumors and brain metastases. The drug has shown high anti-tumor activity as single agent in BRCA mutated preclinical tumor models and synergy and tolerability in combination with chemotherapy. Based on the findings, NMS-293 is currently in clinical developmental Phase II in combination with temozolomide in recurrent glioblastoma.

CAN-3110: Candel Therapeutics

CAN-3110 is a first-in-class, replication-competent herpes simplex virus-1 (HSV-1) oncolytic viral immunotherapy candidate designed with dual activity for oncolysis and immune activation in a single therapeutic. Its activity is designed to be conditional to the expression of Nestin in cancer cells. CAN-3110 is being evaluated in a phase I investigator-sponsored clinical trial in patients with recurrent HGG. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Glioma.

MB-101: Mustang Bio

MB-101 is an IL13Rα2-targeted CAR T cell therapy developed by Mustang Bio, aimed at treating recurrent glioblastoma (GBM) and high-grade gliomas. Currently, the drug is in Phase I stage of clinical trial for the treatment of Glioma.

The Glioma Pipeline Report Provides Insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Glioma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioma Treatment.
Glioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Glioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Glioma market

Explore groundbreaking therapies and clinical trials in the Glioma Pipeline. Access DelveInsight’s detailed report now! @ New Glioma Drugs

Glioma Companies

CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.

Glioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intra-articular
Intraocular
Intrathecal
Intravenous
Oral
Parenteral
Subcutaneous
Topical
Transdermal

Glioma Products have been categorized under various Molecule types such as

Oligonucleotide
Peptide
Small molecule

Unveil the future of Glioma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Glioma Market Drivers and Barriers

Scope of the Glioma Pipeline Report

Coverage- Global
Glioma Companies- CellabMED, Oblato, BioMed Valley Discoveries, PharmAbcine, I-Mab Biopharma, Chimerix, Medicenna Therapeutics, Daiichi Sankyo, Eli Lilly and Company, Candel Therapeutics, AstraZeneca, Aveta Biomics, Angiochem, Arog Pharmaceuticals, Boehringer Ingelheim, BioMimetix, Bexion Pharmaceuticals, CANbridge Life Sciences, Crimson Biopharma, Epitopoietic Research Corporation, Stemgen and others.
Glioma Pipeline Therapies- DS-1001b, Nimotuzumab, Radiotherapy, AP23573, BLZ-100, LY2157299, Temozolomide, Safusidenib, ONC201, PLB1001, YYB-103, and others.
Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Glioma Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Glioma Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Glioma Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Glioma Disease– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
AV-GBM-1: Aivita Biomedical, Inc.
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
DB 107: Denovo BioPharma
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
MB-101: Mustang Bio
Preclinical Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Glioma Disease Key Companies
Glioma Disease Key Products
Glioma Disease- Unmet Needs
Glioma Disease- Market Drivers and Barriers
Glioma Disease- Future Perspectives and Conclusion
Glioma Disease Analyst Views
Glioma Disease Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

Onsena Spa Introduces Revolutionary At-Home Hydrotherapy System for Health, Luxury, and Beauty

Onsena Spa, a pioneer in personal wellness solutions, announces the launch of its revolutionary hydrotherapy system that combines advanced American technology with traditional Japanese onsen healing practices. This at-home spa machine offers a full-body therapeutic experience for ultimate relaxation, comfort, and rejuvenation.

United States – May 5, 2025 – Onsena Spa is proud to introduce its innovative at-home hydrotherapy system, designed to transform any bathroom into a personal wellness sanctuary. By blending cutting-edge American technology with the centuries-old traditions of Japanese onsen, Onsena Spa offers an exclusive luxury wellness experience without the need for appointments or travel.

Vitamia

The Ultimate At-Home Spa Experience

The Onsena Spa system provides users with an advanced bathing solution that includes a variety of health benefits. Featuring microbubble massage jets, mineral ion enrichment, far-infrared heat, and ozone water purification, the system is designed to restore and rejuvenate the body, enhance circulation, relieve muscle and joint pain, reduce stress, and promote skin vitality—all within the comfort of one’s home.

“Our mission was to bring the deeply restorative experience of Japanese onsen healing to everyday living. By merging traditional practices with state-of-the-art American hydrotherapy technology, we’ve created a private wellness sanctuary that elevates health, skin radiance, and total relaxation,” said a spokesperson for Onsena Spa.

A Luxury Wellness Investment

Perfect for busy professionals, wellness enthusiasts, and families, the Onsena Spa is not just a luxury—it’s an investment in overall wellness. Its compact design allows for easy installation in modern homes, adding functionality and elegance to any bathroom.

With the increasing importance of self-care in daily life, the demand for in-home wellness solutions is growing. The Onsena Spa responds to this demand by offering an efficient, stylish, and relaxing experience that promotes both physical health and mental well-being.

A Perfect Addition to One’s Home

Whether seeking daily rejuvenation or looking to unwind after a long day, the Onsena Spa is the ideal choice. It allows users to indulge in therapeutic benefits similar to those found at luxury spas, all from the privacy of their home.

About Onsena Spa

Onsena Spa is an innovative wellness brand dedicated to bringing the benefits of hydrotherapy and traditional onsen healing into homes around the world. Combining advanced American technology with the ancient traditions of Japanese hot springs, Onsena Spa provides a luxurious, at-home wellness experience. The company’s state-of-the-art hydrotherapy systems promote physical and mental well-being through features like microbubble massage jets, far-infrared heat, and ozone water purification. Onsena Spa aims to create personal wellness sanctuaries that support relaxation, rejuvenation, and overall health.

For more information, visit: www.onsenaspa.com

Media Contact
Company Name: Onsena Spa
Contact Person: Communications
Email: Send Email
Country: United States
Website: https://onsenaspa.com/

The 33rd China Cycle 2025 Grandly Commence

“New Quality Productivity, for the Shared Future”, the global cycling grand ceremony opens in Shanghai

On May 5, the 33rd China Cycle Expo 2025 (hereinafter referred to as the “China Cycle”) grandly opens at the Shanghai New International Expo Center. This year’s exhibition, with the theme of “New Quality Productivity, for the Shared Future”, once again achieves a historic breakthrough in scale and content, demonstrating the vigorous vitality of the industry’s development. On the first day of the exhibition, the venue is bustled with people both inside and outside. Exhibitors, buyers and visitors from all over the world gather together, jointly kicking off an annual grand event dedicated to the cycling industry.

China Cycle: Global Industry Barometer UpgradesAgain

China is the world’s largest manufacturer and market of bicycles and electric bicycles, with an annual trade volume accounting for more than 60% of the global total. In 2024, the overall development trend of China’s bicycle industry was continued to improve. Relying on a strong manufacturing base and a broad market, after more than 30 years of development, the China Cycle has become one of the largest and most influential bicycle exhibitions in the world.

This year the exhibition area is further expanded to 160,000 square meters, with a total of 13 professional exhibition halls (W1-W5, E1-E7, N1 Hall), attracting nearly 1,600 companies to participate. The newly opened N1 Hall made its debut, marking a major leap in the layout of the entire hall of the China Cycle in the Shanghai New International Expo Center, providing exhibitors and visitors with a more spacious and professional display platform.

Numerous Highlights: Brands Gather Together, Innovation Leads Future

At the scene, well-known domestic and foreign brands such as GIANT, MERIDA, PHOENIX, FOREVER, TRINX, XIDESHENG, BAFANG, SHIMANO, ABUS, BIANCHI, and FOCUS gather together to compete on the same stage with their latest products and technologies. The exhibition halls are carefully divided into different layouts. E1 focuses on displaying complete vehicle brands, E2-E3 are spare parts areas, E4 is the tire area, W1 focuses on international brands, W4 highlights outdoor cycling equipment, and W5 displays electric motorcycles and innovative products, fully covering the entire industry chain.

In the “2025 CHINA CYCLE Innovation Demonstration Exhibition” area, 70 exhibits representing the industry’s latest technologies and innovative achievements are unveiled, including carbon fiber power-assisted bicycles, electronic speed change systems, polymer fiber rope spokes and other black technology new products, allowing visitors to experience the transformative power of cycling technology at close range.

At the same time, the industry transformation and upgrading demonstration exhibition is officially unveiled. Many specialized and innovative companies such as JIEKE, MAGENE, GOLDEN WHEEL, PHOENIX, and JAVA bring the most cutting-edge green technology solutions to jointly draw a blueprint for the transformation of China’s bicycle industry.

Trade Matching Meeting Starts, International Cooperation HeatsUp

During the exhibition, a two-day trade matchmaking meeting is launched simultaneously, attracting professional purchasing teams from Europe, Southeast Asia, the Middle East and Latin America, focusing on high-end parts, electric bicycles and other hot fields. On the first day, hundreds of efficient negotiations were held, injecting strong momentum into the overseas expansion of Chinese brands and international trade cooperation.

The EventsAreFull Of Excitement,The Cycling Craze Swept The Whole Venue

Inside and outside the exhibition hall, the cycling experience area, outdoor performance show, and technology interactive experience area are bustling. The stunts performed by professional riders triggers cheers, and the test ride area is crowded with people, who experience the convenience and fun of the latest electric-assisted bicycles. The e-sports competition also starts simultaneously, and the cross-border integration of cycling and e-sports ignited the passion of the audience.

The “market area” that was widely acclaimed last year has been fully upgraded this year. It brings together rich content such as star fashion shows, cycling + lifestyle experience areas, new product launches, and cultural experience areas to create a new landmark where cycling culture and fashionable life intersect.

New Cycling Era, Dreams Start Again

The grand opening of the 33rd China Cycle 2025 is showing the vitality of the booming Chinese bicycle industry with a new attitude, and it also builds a broad stage for global cycling enthusiasts and all parties in the industrial chain to share opportunities and create a better future.

The exhibition will last until May 8th, and we welcome more industry colleagues and cycling enthusiasts to join us!

(Source: China Cycle Organizing Committee)

Media Contact
Company Name: OTOBTB Cultural Development Co.,Ltd
Contact Person: Kira Pan
Email: Send Email
Phone: 021-32513000-859
City: Shanghai
Country: China
Website: http://www.otobtb.com

Carlos Scarpero Helps Veterans with Bad Credit Unlock the Door to Homeownership with VA Loans

Carlos Scarpero, a mortgage broker with Edge Home Finance

Carlos Scarpero of Edge Home Finance helps Ohio veterans with poor credit access VA home loans through expert guidance, flexible lender options, and practical solutions

Veterans facing credit challenges now have a powerful ally in the mortgage process. Carlos Scarpero, a trusted mortgage broker based in Dayton, Ohio, is offering expert guidance to help veterans secure VA home loans, even with poor credit.

In his newly published article, “How to Get a VA Home Loan with Bad Credit,” Scarpero outlines practical steps for veterans to qualify for home financing using their VA benefits, dispelling common myths about credit score requirements and loan eligibility.

“Many veterans assume bad credit disqualifies them from homeownership,” says Scarpero. “That’s simply not true. With the right guidance and a little planning, it’s possible to buy a home—even with less-than-perfect credit.”

Key Insights from the Guide:

No Minimum Credit Score Set by the VA

The VA doesn’t require a minimum credit score for home loans. However, individual lenders often set their own thresholds, commonly around 580 to 620.

Lender Flexibility Exists

Some lenders may consider applicants with scores as low as 500, especially if other financial strengths, such as stable income or savings, are present.

Manual Underwriting as an Option

For borrowers with unique financial circumstances or limited credit history, manual underwriting allows lenders to evaluate alternative data like rent and utility payment history.

Handling Collections and Financial Setbacks

Scarpero details how medical collections, child support, credit card debt, and IRS obligations are treated during the VA loan process—and how to address them effectively.

Post-Bankruptcy and Foreclosure Recovery

Veterans with a history of bankruptcy or foreclosure may still qualify for a VA loan, often with shorter waiting periods compared to other mortgage options.

About Carlos Scarpero

Carlos Scarpero is a licensed mortgage broker with Edge Home Finance, specializing in VA and non-traditional home loans. With over a decade of experience and a passion for helping veterans achieve homeownership, he serves clients throughout Ohio, including Dayton, Cincinnati, and Columbus.Scarpero’s approach is built on transparency, education, and tailored solutions—especially for those who may feel left behind by traditional lenders.

To read the full guide or get started with a VA loan, visit:

www.scarpero.com/how-to-get-a-va-home-loan-with-bad-credit

Media Contact
Company Name: Edge Home Finance
Contact Person: Carlos Scarpero
Email: Send Email
Phone: 937-572-3713
City: Dayton
State: Ohio
Country: United States
Website: https://www.scarpero.com/

From Banking to Breakouts: How Iris Yuan is Redefining Financial Freedom One Hour at a Time

Former banker Iris Yuan left corporate life behind to teach minimalist trading strategies, offering a blueprint for financial freedom that’s less about hustle and more about mastery.

In a world where traditional career ladders are looking more like treadmills, some professionals are finding new ways off the ride. Iris Yuan is one of them.

A former corporate banker, Iris Yuan, once spent her days buried in spreadsheets, board meetings, and a rising sense that something wasn’t adding up. The salary was fine. The titles looked good on LinkedIn. But freedom? Nowhere in sight.

Today, Iris Yuan is a financial educator, trading mentor, and founder of The Stock Sniper, where she helps professionals reclaim their time and rebuild their financial futures through skills most never learned in school. Her method? Focused, minimalist trading strategies designed to fit into real life, not replace it.

“Financial independence isn’t just about money anymore,” Iris says. “It’s about time. Control. Options. We were taught to chase titles but nobody taught us how to own our time.”

Her story is becoming a familiar one. Across industries, career professionals are waking up to a brutal truth: long hours and loyalty don’t guarantee security anymore. Pensions are shrinking. Retirement is being pushed out of reach. And the old promises of stability are starting to crack.

Iris Yuan didn’t pivot overnight. She spent years learning market patterns, testing small trades, building a system that didn’t depend on high-frequency chaos or endless news cycles. What she found was surprising and refreshingly simple.

“I realized you could spend all day chasing trades and still lose,” she says. “Or you could learn to spot a few good setups, protect your downside, and let time do the heavy lifting.”

Minimalist trading, she explains, isn’t about doing less to earn more. It’s about stripping out the noise so you can make smarter decisions faster.

It’s a message that’s resonating as the idea of financial freedom itself shifts. More people are realizing that real wealth isn’t just a bigger paycheck. It’s autonomy. Skills. Breathing room.

“The best investment you’ll ever manage is yourself,” Iris says. “Money can vanish. Markets can change. But skills? They’re permanent.”

Through her educational programs, Yuan isn’t promising lottery tickets or overnight success stories. She’s offering something rarer: practical literacy in a world that often profits from confusion.

As founder of The Stock Sniper, she’s part of a growing movement that sees financial literacy not as a luxury, but as a survival skill for the next generation of entrepreneurs, freelancers, and quietly rebellious professionals.

One hour a day. One skill at a time. For Yuan, it’s not about chasing more, it’s about finally having enough.

About Iris Yuan

Iris Yuan is a former corporate banker turned financial educator and trading mentor. As the founder of The Stock Sniper, she is dedicated to simplifying financial literacy and helping professionals build independent wealth through time-efficient strategies. Her work focuses on empowering individuals to master essential skills for a modern, autonomous financial future.

Learn more about her educational programs at https://www.thestocksniper.net/iriswebinar1

Media Contact
Company Name: The Stock Sniper
Contact Person: Iris Yuan
Email: Send Email
Address:10 Anson Rd, #18-13 International Plaza
City: Singapore 079903
Country: Singapore
Website: https://www.thestocksniper.net

Russell Rabichev to Host Invite Only Event on Applying the Law of Attraction in Business and Leadership

Invitation-only session explores how intentional thinking influences outcomes for entrepreneurs and executives

The Law of Attraction Event Flyer

Los Angeles, CA – Russell Rabichev, a multi-entrepreneur and journalist, will host a private, invitation-only event in Los Angeles focused on the real-world application of the Law of Attraction. The event, “Russell Rabichev: The Law of Attraction ” is designed for entrepreneurs, executives, CEOs, e-commerce professionals, and business owners seeking insight into how mindset and intentional focus can shape tangible results.

Known for his cross-industry experience and systems-based thinking, Rabichev will lead attendees through a structured discussion on how internal alignment, mental clarity, and consistent intention contribute to strategic decision-making and leadership effectiveness. Rather than promoting abstract theory, the session will focus on practical cognitive tools that Rabichev has used to guide personal and business growth.

The event will highlight how visualization, focused attention, and belief systems may influence behavior, creativity, and professional outcomes over time. Participants will be encouraged to reflect on their mental habits, values, and leadership posture in the context of their current roles and responsibilities.

“Focus directs action, and repeated action drives results,” Rabichev has previously stated in his writing. The event will explore how these dynamics play out in high-pressure environments, particularly in entrepreneurship and organizational leadership.

This session avoids promotional content and sales messaging. There will be no product pitches or coaching services offered. Instead, the aim is to create a setting for thoughtful exchange among professionals who wish to explore the role of intentional thinking in their decision-making process.

The private venue will be located in central Los Angeles. Attendance is limited and available by invitation only, with final details shared directly with confirmed guests.

Participants will include a select group of startup founders, business owners, consultants, and innovation leaders from Rabichev’s professional network. The discussion will be conducted in a confidential, peer-level format to encourage open and practical dialogue.

About Russell Rabichev

Russell Rabichev is a Los Angeles-based Rabbi, entrepreneur, and journalist working across media, business strategy, and personal development. His focus is on the intersection of mindset, leadership behavior, and systems thinking, and he is recognized for his process-driven approach to innovation and growth.

Media Contact
Company Name: Rabbi
Contact Person: Russell Rabichev
Email: Send Email
Phone: 1 (310) 747-5505
City: Los Angeles
State: Calfiornia
Country: United States
Website: https://rabbi.love/